Publication Author: Urban_Nicole

• Activation of the MEK-S6 pathway in high-grade ovarian cancers.

  Ventura AP, Radhakrishnan S, Green A, Rajaram SK, Allen AN, O’Briant K, Schummer M, Karlan B, Urban N, Tewari M, Drescher C, Knudsen BS. Activation of the MEK-S6 pathway in high-grade ovarian cancers. Appl Immunohistochem Mol Morphol. 2010 Dec;18(6):499-5

  rakerr2

  December 1, 2010

• Breast cancer genomics: normal tissue and cancer markers.

  Schummer M, Beatty D, Urban N. Breast cancer genomics: normal tissue and cancer markers. Ann N Y Acad Sci. 2010 Oct;1210:78-85. doi: 10.1111/j.1749-6632.2010.05803.x.

  rakerr2

  October 1, 2010

• Use of a single-chain antibody library for ovarian cancer biomarker discovery.

  Ramirez AB, Loch CM, Zhang Y, Liu Y, Wang X, Wayner EA, Sargent JE, Sibani S, Hainsworth E, Mendoza EA, Eugene R, Labaer J, Urban ND, McIntosh MW, Lampe PD. Use of a single-chain antibody library for ovarian cancer biomarker discovery. Mol Cell Proteomics

  rakerr2

  July 1, 2010

• Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer.

  Andersen MR, Goff BA, Lowe KA, Scholler N, Bergan L, Drescher CW, Paley P, Urban N. Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer. Gynecol Oncol. 2010 Mar;116(3):378-83. Epub 2009 Nov 28.

  rakerr2

  March 1, 2010

• Comparison of breast cancer to healthy control tissue discovers novel markers with potential for prognosis and early detection.

  Schummer M, Green A, Beatty JD, Karlan BY, Karlan S, Gross J, Thornton S, McIntosh M, Urban N. Comparison of breast cancer to healthy control tissue discovers novel markers with potential for prognosis and early detection. PLoS One. 2010 Feb 9;5(2):e9122.

  rakerr2

  February 9, 2010

• Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study.

  Anderson GL, McIntosh M, Wu L, Barnett M, Goodman G, Thorpe JD, Bergan L, Thornquist MD, Scholler N, Kim N, O’Briant K, Drescher C, Urban N. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst. 2010 J

  rakerr2

  January 6, 2010

• Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition.

  Bendoraite A, Knouf EC, Garg KS, Parkin RK, Kroh EM, O’Briant KC, Ventura AP, Godwin AK, Karlan BY, Drescher CW, Urban N, Knudsen BS, Tewari M. Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a m

  rakerr2

  January 1, 2010

• Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer biomarker discovery.

  Pitteri SJ, JeBailey L, Faça VM, Thorpe JD, Silva MA, Ireton RC, Horton MB, Wang H, Pruitt LC, Zhang Q, Cheng KH, Urban N, Hanash SM, Dinulescu DM. Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer b

  rakerr2

  November 19, 2009

• Evaluating erythropoietin-associated tumor progression using archival tissues from a phase III clinical trial.

  Miller CP, Lowe KA, Valliant-Saunders K, Kaiser JF, Mattern D, Urban N, Henke M, Blau CA. Evaluating erythropoietin-associated tumor progression using archival tissues from a phase III clinical trial. Stem Cells. 2009 Sep;27(9):2353-61.

  rakerr2

  September 1, 2009

• Quantitative proteomics analysis integrated with microarray data reveals that extracellular matrix proteins, catenins, and p53 binding protein 1 are important for chemotherapy response in ovarian cancers.

  Pan S, Cheng L, White JT, Lu W, Utleg AG, Yan X, Urban ND, Drescher CW, Hood L, Lin B. Quantitative proteomics analysis integrated with microarray data reveals that extracellular matrix proteins, catenins, and p53 binding protein 1 are important for chemo

  rakerr2

  August 1, 2009